共 19 条
[1]
Paulos C.M., Turk M.J., Breur G.J., Low P.S., Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis, Advanced Drug Delivery Reviews, 56, 8, pp. 1205-1217, (2004)
[2]
Taylor P.C., Feldmann M., Anti-TNF biologic agents: Still the therapy of choice for rheumatoid arthritis, Nat Rev Rheumatol, 5, pp. 578-582, (2009)
[3]
Lohse A., Despaux J., Auge B., Toussirot E., Wendling D., Pneumococcal polyarticular septic arthritis in a patient with rheumatoid arthritis, Rev Rhum Engl Ed, 66, pp. 344-346, (1999)
[4]
Yamanaka H., Tanaka Y., Sekiguchi N., Inoue E., Saito K., Kameda H., Iikuni N., Nawata M., Amano K., Shinozaki M., Takeuchi T., Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM), Modern Rheumatology, 17, 1, pp. 28-32, (2007)
[5]
Listing J., Strangfeld A., Kary S., Rau R., Von Hinueber U., Stoyanova-Scholz M., Gromnica-Ihle E., Antoni C., Herzer P., Kekow J., Schneider M., Zink A., Infections in patients with rheumatoid arthritis treated with biologic agents, Arthritis and Rheumatism, 52, 11, pp. 3403-3412, (2005)
[6]
Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., Rahman M.U., The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial, Arthritis and Rheumatism, 54, 4, pp. 1075-1086, (2006)
[7]
Takeuchi T., Tatsuki Y., Nogami Y., Ishiguro N., Tanaka Y., Yamanaka H., Kamatani N., Harigai M., Ryu J., Inoue K., Kondo H., Inokuma S., Ochi T., Koike T., Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, 67, 2, pp. 189-194, (2008)
[8]
Doran M.F., Crowson C.S., Pond G.R., O'Fallon W.M., Gabriel S.E., Predictors of infection in rheumatoid arthritis, Arthritis Rheum, 46, pp. 2294-2300, (2002)
[9]
Rosenblum H., Amital H., Anti-TNF therapy: Safety aspects of taking the risk, Autoimmun Rev, 10, pp. 563-568, (2011)
[10]
Dixon W.G., Watson K., Lunt M., Hyrich K.L., Silman A.J., Symmons D.P.M., Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register, Arthritis and Rheumatism, 54, 8, pp. 2368-2376, (2006)